Pulmonary Medicine

Host: Linda Bernstein, Pharm.D.

In light of the COVID-19 pandemic, the Centers for Disease Control and Prevention, or the CDC, plans to use pharmacies to increase access to the COVID-19 vaccine when it is ready for distribution. In this episode of The Drug Report, Linda Bernstein will explain the CDC’s recently-developed Vaccination Program Interim Playbook.

Published November 17, 2020

Host: Linda Bernstein, Pharm.D.

The Food and Drug Administration announced that Remdesivir is the first treatment for COVID-19 to receive their approval. To help us better understand this antiviral agent, Dr. Linda Bernstein discusses emerging studies uncovering the benefits and limitations of Remdesivir.

Published November 6, 2020

Guest: Abigail T. Berman, MD, MSCE

The risk of COVID-19 has become a significant factor to consider when selecting between SBRT and surgery for patients with early-stage lung cancer. Dr. Abigail Berman, a radiation oncologist at the University of Pennsylvania Abramson Cancer Center in Philadelphia, discusses how she works with patients to decide on the best treatment for them.

Host: Timothy Aksamit, MD

Guest: Amy Levinger, MSN, FNP-C

Guest: David E. Griffith, MD

The prevalence of non-tuberculous mycobacterial (NTM) lung disease in the United States has almost doubled between 2008 and 2015. But despite this increase, its diagnosis can often be delayed, which is why pulmonary nurse practitioner Amy Levinger and Dr. David Griffith join Dr. Tim Aksamit to discuss the diagnostic criteria, tools that can help us make a timely diagnosis of NTM lung disease, and more.

For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.

This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.

Host: Xavier Soler, MD, PhD

Guest: Nicola A. Hanania, MD, MS, FCCP

To help us address the current lack of awareness of uncontrolled or symptomatic asthma in all stages of the disease, Dr. Xavier Soler is joined by Dr. Nicola Hanania, Associate Professor of Pulmonary Medicine and Director of the Airway Clinical Research Center at Baylor College of Medicine in Houston, Texas. Together, they’ll discuss how we can better recognize and treat our patients with uncontrolled asthma.

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.

Host: David E. Griffith, MD

Guest: Amy Levinger, MSN, FNP-C

Guest: Timothy Aksamit, MD

The care team supporting a patient with mycobacterium avium complex, or MAC, lung disease is just as important as the treatment itself. Joining Dr. David Griffith to discuss how we can provide optimal treatment using established guideline-based strategies all while protecting patients’ quality of life are Dr. Tim Aksamit and pulmonary nurse practitioner Amy Levinger.

For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.

This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.

Host: Tom Corbridge, MD, FCCP

Guest: Matt Hegewald, MD FCCP

With uncontrolled asthma placing such a tremendous burden on our patients and our society, how can we use the latest treatment guidelines to help alleviate that burden? Dr. Matt Hegewald is here to talk about the new and emerging guideline-based treatments for uncontrolled asthma, like long-acting muscarinic antagonists.

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.

Host: Tom Corbridge, MD, FCCP

Guest: Navitha Ramesh, MD, FCCP

Now that long-acting muscarinic receptor antagonists (LAMAs) have entered the scene, Dr. Tom Corbridge is joined by Dr. Navitha Ramesh, a pulmonologist and critical care physician at UPMC, to review some patient cases demonstrating how LAMAs may be changing the way we approach step-up treatment for some patients with asthma.

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.

Host: Megan Carreon, MHA, RRT

Guest: Amy Levinger, MSN, FNP-C

Guest: Timothy Aksamit, MD

There are numerous factors that contribute to an overall wellness of patients with of NTM refractory MAC lung disease. Listen in as Megan Carreon, Assistant Professor with the Division of Respiratory Care at UT Health San Antonio, Texas, sits down with pulmonary nurse practitioner Amy Levinger from NYU Langone Health and Dr. Tim Aksamit, Associate Professor of Pulmonary and Critical Care Medicine at Mayo Clinic.

For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.

This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.

Host: Andrew Wilner, MD, FACP, FAAN

Guest: William W. Li, MD

How do the lungs of healthy patients differ from the lungs of patients with COVID-19 or the flu? That’s the exact question Dr. William Li wanted to answer, and now, he’s sharing the results of his study that was recently published in the New England Journal of Medicine.

Published August 12, 2020